Small-cell lung cancer: insights and new treatment options centering around DLL3
Small-cell lung cancer: insights and new treatme
Immunotherapy combinations in advanced-stage disease
Immunotherapy combinations in advanced-stage dis
EGFR-mutated NSCLC: practice-changing results and other notable findings
EGFR-mutated NSCLC: practice-changing results an
Innovative agents directed against RET, Trop-2, KRASG12C and HER2
Innovative agents directed against RET, Trop-2,
ALK-targeted adjuvant treatment and perioperative immunotherapy
ALK-targeted adjuvant treatment and perioperativ
Preface – ESMO Lung Cancer 2023
Preface – ESMO Lung Cancer 2023 © priv
Conventional chemotherapy combined with PD-1/PD-L1
Conventional chemotherapy combined with PD-1/PD-
Emerging therapies in solid tumors
Emerging therapies in solid tumors BMS-986253 plus
New strategies with PD-1/PD-L1 blockade in lung cancer
New strategies with PD-1/PD-L1 blockade in lung cancer
Preface – ESMO IO 2022
Preface - ESMO IO 2022 Matteo Simonelli, MD, Depart
